Načítá se...
Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs
Reimbursement decisions on new oncology drugs are now often made while uncertainty remains about a drug's risk–benefit profile. One consequence of this is a delay in patient access to valuable new medicines. We share our perspectives on strategies to mitigate sources of uncertainty in the healt...
Uloženo v:
| Vydáno v: | J Mark Access Health Policy |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Routledge
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6346722/ https://ncbi.nlm.nih.gov/pubmed/30719243 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/20016689.2018.1562861 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|